The Commission announced that it is formally granting conditional marketing authorisation in the European Union for Novavax's Nuvaxovid vaccine
following a recommendation from the European Medicines Agency (EMA), which found the new COVID-19 vaccine to be safe and effective, and following a green light from Member States- .
Commissioner Stella Kyriakidou highlighted that this is the first vaccine in the EU portfolio and the first protein-based vaccine that shows promising results against coronavirus.
"Vaccination and booster doses to increase protection against COVID-19 are now more important than ever if we are to stem the tide of infections and tackle the emergence and spread of new variants," said Commissioner Kyriakidou.
She stressed that today the European Union is offering another safe and effective vaccine while making a new call for vaccination.
According to the Commission's contract with Novavax, signed on 4 August this year, the company can deliver up to 100 million doses to the EU in the first quarter of 2022, while Member States have the option to purchase an additional 100 million doses in 2022 and 2023.
The first tranches are expected to reach Member States in the first months of 2022, with Member States having ordered 27 million tranches for the first quarter of the year.
Commission President Ursula von der Leyen was particularly pleased with the approval of the new vaccine at this time, as the Omicron variant is spreading rapidly and increased vaccination is becoming even more necessary.
"This is the fifth safe and effective vaccine in our portfolio, which offers additional protection to the citizens of Europe against the pandemic."
"Hopefully this licensing will be a strong incentive for all those who have not yet been vaccinated or received a booster dose to do so now," she added."
Source: CNA
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times[/SIZE]
Source
